Labiotech.eu

exelixis ipsen cancercabozantinib renal liver endometrial nsclc

News and Trends 1 Mar 2016

French Ipsen closes €700M deal for Californian Cancer Drug

Ipsen is paying Exelixis $200M upfront, plus $545M in future milestones to acquire commercialization rights for a multi-organ cancer candidate outside US, Canada and Japan. California-based Exelixis has found an European partner to license the small molecule drug, cabozantinib. Ipsen, a French biotech group, will have comercialization rights for cabozantinib worldwide, except in the US and […]

March 1, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 1 Mar 2016

Overcoming the Challenges of Text-Mining in Biotech Research

A few weeks ago we introduced you to the concept of text-mining in Biotech through this article. Now that you’re more familiar with the concept, let’s ‘mine’ a bit into the current challenges in this field and how to overcome them. Data produced through Biotech research grows with an incredible rate. Everyday, scientists are finding […]

March 1, 2016 - 4 minutesmins - By Jerome Topsent

News and Trends 1 Mar 2016

Here’s why this leading EU Investor turned to NASH

Akarna Therapeutics (US & UK) just raised $15M (€13M) in a series B round led by Forbion Partners – one of the leading VCs from Europe. Also run by existing New York investors New Science Ventures and Third Point, the round purpose was to raise funding to develop a new drug for the liver disease Non-alcoholic steatohepatitis (NASH). I […]

March 1, 2016 - 4 minutesmins - By Philip Hemme

News and Trends 29 Feb 2016

Our Top 5 Articles on Biotech & Rare Disease

Today is Rare Disease Day 2016. Because it is an important field for Biotech, we went back to review some of our best articles on the topic from the Labiotech archives. Here are some of our best – in addition to an overview of 7 Rare diseases and who in Biotech is working on them. Nº […]

February 29, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 29 Feb 2016

Exploiting the Power of NGS to Diagnose Rare Diseases

Diploid (Belgium) is using genome sequencing data to diagnose rare diseases – and is now charging only if its algorithms can match the genome to a specific rare disease. Patients of rare diseases often struggle with the lack of therapies options – an empty space where Biotechs seem to thrive. But therapy availability is not the […]

February 29, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 29 Feb 2016

It’s Rare Disease Day 2016: Here are 7 Indications which Biotech is Fighting

According to the European Organisation for Rare Disease, there are 20–30 million people in Europe alone who are affected by one of an estimated 6,000 rare diseases. These include many rare genetic disorders, such as Duchenne’s muscular dystrophy, but also rare forms of cancer and auto-immune disease. The term rare can, therefore, be misleading as many diseases are entering […]

February 29, 2016 - 6 minutesmins - By Dani Bancroft

News and Trends 27 Feb 2016

What happened this week? European Biotechs on NASDAQ, Onxeo’s CEO Interview, NGS Battle

Monday: Meet the CEO of a Confident Orphan Oncology Biotech from France & Denmark Tuesday: 7 Trendy European Biotechs Listed on the NASDAQ in 2016 Wednesday: Your Microbiome even Impacts how Tall you are! Thursday: NGS Battle: Illumina is now suing Oxford Nanopore (and it looks suspicious) Friday: Faces of Bioart: Depicting the Psychology of Petri […]

February 27, 2016 - 1 minutemin - By Philip Hemme

News and Trends 26 Feb 2016

A New Super-Antibody against Ebola has been Isolated

Humabs BioMed (Switzerland), in collaboration with institutional partners has succeeded in isolating new antibodies against the Ebola virus and turned them into a potential therapy against it. Humabs discovers monoclonal antibodies by doing blood analysis of survivors to given infectious diseases. For example, if one wants the cure for the flu, it looks into people […]

February 26, 2016 - 3 minutesmins - By Denise Neves Gameiro

suzanne ankler bioart zoosemiotics MRI butterfly vanitas petri remote sensing 3D print rainbow loom

News and Trends 26 Feb 2016

Faces of Bioart: Depicting the Psychology of Petri Dishes and Chromosomes with Suzanne Anker

Suzanne Anker is a must-know in the BioArt community, with expositions around the world and directing her own BioArt lab in New York. She explores artefacts that have become icons of Biology – such as chromosomes, MRI scans and Petri dishes. Around the same time the Human Genome Project was initiated, Anker exhibited Zoosemiotics (1993). […]

February 26, 2016 - 4 minutesmins - By Denise Neves Gameiro

News and Trends 26 Feb 2016

Biotech of the week: Kallistem, producing Functional In vitro Spermatozoids in France

This week, we leave Lisbon, Portugal and head up to Lyon, the so-called gastronomical capital of France. Besides bird watching, a beautiful cathedral and a multi-purpose Roman amphitheatre, and of course delicious food, Lyon is where Kallistem, our Biotech of the Week, is located. City: Lyon, France Founded: 2012 Employees: 7 (as of 02/2016) Financial Data: N/A CEO: […]

February 26, 2016 - 2 minutesmins - By Joachim Eeckhout

News and Trends 25 Feb 2016

NGS Battle: Illumina is now suing Oxford Nanopore (and it looks suspicious)

NGS-Giant Illumina (US) is suing Oxford Nanopore (UK), the Unicorn ready to disrupt gene sequencing. What’s the story? Illumina currently has the monopoly on NGS equipment, and Illumina’s machines make a common (and bulky) fixture in labs all over the world. In the future, many hospitals will move into data-driven medicine and NGS plays an important […]

February 25, 2016 - 3 minutesmins - By Denise Neves Gameiro

nestle health sciences pronutria investment amino acids food

News and Trends 25 Feb 2016

Boston Food Biotech Gets €38M from Nestlé

Pronutria (US) is a start-up out of Flagship Ventures developing nutritional therapies which has now gotten a huge equity investment from Nestlé Health Science (Switzerland). Pronutria is a cool Biotech start-up taking an innovative approach to treat diseases caused by amino acid imbalance, such as muscle loss, and neurological and liver complications. Besides being essential for protein synthesis, […]

February 25, 2016 - 3 minutesmins - By Denise Neves Gameiro

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

French Ipsen closes €700M deal for Californian Cancer Drug

Overcoming the Challenges of Text-Mining in Biotech Research

Here’s why this leading EU Investor turned to NASH

Our Top 5 Articles on Biotech & Rare Disease

Exploiting the Power of NGS to Diagnose Rare Diseases

It’s Rare Disease Day 2016: Here are 7 Indications which Biotech is Fighting

What happened this week? European Biotechs on NASDAQ, Onxeo’s CEO Interview, NGS Battle

A New Super-Antibody against Ebola has been Isolated

Faces of Bioart: Depicting the Psychology of Petri Dishes and Chromosomes with Suzanne Anker

Biotech of the week: Kallistem, producing Functional In vitro Spermatozoids in France

NGS Battle: Illumina is now suing Oxford Nanopore (and it looks suspicious)

Boston Food Biotech Gets €38M from Nestlé

Subscribe to our newsletter to get the latest biotech news!